A Phase I Safety Study of Farletuzumab (MORAb-003), Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Subjects With Platinum-sensitive Ovarian Cancer.
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Carboplatin; Doxorubicin liposomal; Farletuzumab
- Indications Ovarian cancer
- Focus Adverse reactions
- 28 Nov 2015 Results published in the Gynecologic Oncology
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2012 Planned End Date changed from 1 May 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.